In the last trading session, 2.83 million ATAI Life Sciences N.V (NASDAQ:ATAI) shares changed hands as the company’s beta touched 0.94. With the company’s per share price at $1.58 changed hands at $0.17 or 12.06% during last session, the market valuation stood at $276.91M. ATAI’s last price was a discount, traded about -80.38% off its 52-week high of $2.85. The share price had its 52-week low at $1.02, which suggests the last value was 35.44% up since then. When we look at ATAI Life Sciences N.V’s average trading volume, we note the 10-day average is 1.4 million shares, with the 3-month average coming to 724.85K.
Analysts gave the ATAI Life Sciences N.V (ATAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATAI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ATAI Life Sciences N.V’s EPS for the current quarter is expected to be -0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI was in green as seen at the end of in last trading. With action 46.30%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 12.06%, with the 5-day performance at 46.30% in the green. However, in the 30-day time frame, ATAI Life Sciences N.V (NASDAQ:ATAI) is 43.64% up. Looking at the short shares, we see there were 9.59 million shares sold at short interest cover period of 18.44 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 73.67% from its current market value. According to analyst projections, ATAI’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -279.75% plunge from its current level, while the stock would need to soar -279.75% for it to hit the projected low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Data shows that the ATAI Life Sciences N.V share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -18.56% over the past 6 months, a -212.00% in annual growth rate that is considerably lower than the industry average of 17.40%. Year-over-year growth is forecast to reach 43.30% up from the last financial year.
4 analysts are of the opinion that ATAI Life Sciences N.V’s revenue for the current quarter will be 370k. The company’s revenue for the corresponding quarters a year ago was 87k and 18k respectively. The estimates for the next quarter sales put growth at 1,955.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 44.19%. The 2024 estimates are for ATAI Life Sciences N.V earnings to decrease by -222.86%.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.99% of ATAI Life Sciences N.V shares while 27.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 30.06%. There are 27.06% institutions holding the ATAI Life Sciences N.V stock share, with WALLEYE CAPITAL LLC the top institutional holder. As of 2024-06-30, the company held 1.7388% of the shares, roughly 2.76 million ATAI shares worth $3.67 million.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.7111% or 2.72 million shares worth $3.62 million as of 2024-06-30.
